Doloromics has appointed Dr. Chris Flores as their new President and Chief Research and Development Officer. In this role, Dr. Flores will be responsible for leading the Doloromics portfolio of drug discovery and development programmes, two of which are scheduled to launch in early 2022, while building relationships with strategic partners and collaborators in support of these efforts.
“After an extensive and diverse experience in the Pharmaceutical and Consumer sectors of Johnson & Johnson, I’m both thrilled and privileged to commit the full measure of my expertise and passion in executing the core mission of Doloromics, to eradicate pain in patients who remain tragically underserved by current standards of care”, said Dr. Flores.
Dr. Flores has held several executive positions, including Vice President of Neuroscience at Johnson & Johnson, La Jolla R&D Site Head, Pain Franchise Strategy Leader, Head of Pain Discovery and Global External Innovation Head of Discovery Sciences within Janssen Research & Development as well as Head of Emerging Science and Innovation Strategy for J&J Consumer Companies.
